Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice
Alzheimer s & Dementia,
Год журнала:
2024,
Номер
20(9), С. 6115 - 6132
Опубликована: Авг. 3, 2024
Abstract
INTRODUCTION
We
developed
a
multimarker
blood
test
result
interpretation
tool
for
the
clinical
dementia
practice,
including
phosphorylated
(P‐)tau181,
amyloid‐beta
(Abeta)42/40,
glial
fibrillary
acidic
protein
(GFAP),
and
neurofilament
light
(NfL).
METHODS
measured
plasma
biomarkers
with
Simoa
(
n
=
1199),
applied
LASSO
regression
biomarker
selection
receiver
operating
characteristics
(ROC)
analyses
to
determine
diagnostic
accuracy.
validated
our
findings
in
two
independent
cohorts
constructed
visualization
approach.
RESULTS
P‐tau181,
GFAP,
NfL
were
selected.
This
combination
had
area
under
curve
(AUC)
83%
identify
amyloid
positivity
pre‐dementia
stages,
AUC
87%–89%
differentiate
Alzheimer's
or
controls
from
frontotemporal
dementia,
74%–76%
Lewy
bodies.
Highly
reproducible
AUCs
obtained
cohorts.
The
resulting
includes
UpSet
plots
visualize
stand‐alone
results
density
combined.
DISCUSSION
Our
is
ready
testing
real‐world
settings.
Highlights
practice.
P‐tau,
NfL.
particularly
useful
diagnosis.
Язык: Английский
Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease
The Journal of Prevention of Alzheimer s Disease,
Год журнала:
2025,
Номер
unknown, С. 100065 - 100065
Опубликована: Янв. 1, 2025
Язык: Английский
Core blood biomarkers of Alzheimer's disease: A single-center real-world performance study
The Journal of Prevention of Alzheimer s Disease,
Год журнала:
2025,
Номер
12(2), С. 100027 - 100027
Опубликована: Янв. 23, 2025
Язык: Английский
The value of serum glial fibrillary acidic protein as a biomarker of astrogliosis in different neurological diseases
Clinica Chimica Acta,
Год журнала:
2025,
Номер
unknown, С. 120248 - 120248
Опубликована: Март 1, 2025
Язык: Английский
Alzheimer’s disease clinical decision points for two plasma p-tau217 laboratory developed tests in neuropathology confirmed samples
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Июль 29, 2024
ABSTRACT
INTRODUCTION
We
evaluated
the
diagnostic
performance
of
two
commercial
plasma
p-tau217
immunoassays
compared
to
CSF
testing
and
neuropathology.
METHODS
170
samples
from
University
British
Columbia
Hospital
Clinic
for
Alzheimer’s
(AD)
Related
Disorders
were
analyzed
using
Fujirebio
ALZpath
assays.
Decision
points
determined
autopsy
findings
as
standard.
RESULTS
had
similar
overall
analytical
clinical
performance,
with
distinct
decision
each
assay.
Based
on
finding,
both
assays
identified
individuals
AD
other
neurodegenerative
diseases
(ALZpath
AUC
=
0.94,
AUC=
0.90).
The
assay
detected
pathology
at
milder
disease
stages
DISCUSSION
Our
study
reinforces
utility
an
biomarker.
Differences
in
test
suggest
specific
approach
is
required
practice.
Язык: Английский